Evaluation of Serum Ferritin, Creatinine, and Liver Enzymes in Patients with Beta-Thalassemia After Administration of Deferasirox

The study on 85 patients with ß-thalassemia in Kirkuk, Iraq, found that deferasirox, an oral iron chelator, effectively reduced serum ferritin levels in 55.3% of patients, indicating a decrease in iron overload. Some adverse effects were observed, including elevated serum creatinine in 25.8% of patients, elevated liver enzymes, and hair loss in 2 patients. Despite these side effects, deferasirox was generally well-tolerated, and its adverse effects could be managed by adjusting the dosage. The study concludes that deferasirox is a suitable treatment for managing iron overload in ß-thalassemia patients.